Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies by Mugo, RM, Orindi, B, Shee, FM, Bellamy, D, Ewer, KJ, Bejon, P

Clinical development of viral vectored vaccines against MERS-COV by Ewer, K, Folegatti, P, Bellamy, D, Mair, C, Alharbi, N, Lambe, T, Wright, D, Warimwe, G, Gilbert, S

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infectio... by Sklar, MJ, Maiolatesi, S, Patterson, N, Berrie, E, Bellamy, D, Bittaye, M, Ewer, K, Lawrie, A, Hill, A

Efficacy and safety of a modified Vaccinia Ankara-NP+M1 vaccine combined with QIV in people aged 65 and older: a randomised controlled clinical trial (INVICTUS) by Butler, C, Ellis, C, Folegatti, P, Swayze, H, Allen, J, Lawrie, A, Yu, L, Shanyinde, M, Bellamy, D, Mair, C, Flaxman, A, Ewer, KJ, Gilbert, S

Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection... by Noe, A, Datoo, M, Flaxman, A, Jenkin, D, Bellamy, D, Makinson, R, Morter, R, Ramos Lopez, F, Sheridan, J, Voukantsis, D, Prasad, N, Hill, A, Ewer, K, Spencer, A

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo by Ewer, K, Smith, C, Sarkar, E, Bowyer, G, Rampling, T, Mair, C, Bellamy, D, Sabir, S, Davies, C, Venkatraman, N, Conway-Jones, R, Campbell, D, Boyer, C, Hill, A, Thomson, E, Snape, M

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line by Folegatti, P, Bellamy, D, Flaxman, A, Mair, C, Ellis, C, Ramon, R, Lopez, F, Mitton, C, Baker, M, Poulton, I, Lawrie, A, Roberts, R, Minassian, A, Ewer, K, Evans, T, Hill, A, Gilbert, S

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine by Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies by Folegatti, P, Flaxman, A, Jenkin, D, Makinson, R, Kingham, L, Bellamy, D, Ramos Lopez, F, Sheridan, J, Poulton, I, Aboagye, J, Tran, N, Mitton, C, Roberts, R, Lawrie, A, Hill, A, Ewer, KJ, Gilbert, S

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial by Folegatti, P, Harrison, K, Preciado-Llanes, L, Ramos Lopez, F, Bittaye, M, Kim, Y, Flaxman, A, Bellamy, D, Makinson, R, Sheridan, J, Tilley, M, Tran, N, Jenkin, D, Poulton, I, Lawrie, A, Roberts, R, Berrie, E, Hill, A, Ewer, K, Reyes-Sandoval, A

Prime and target immunization protects against liver-stage malaria in mice by Gola, A, Silman, D, Walters, A, Uderhardt, S, Salman, A, Halbroth, B, Bellamy, D, Bowyer, G, Powlson, J, Baker, M, Venkatraman, N, Poulton, I, Berrie, E, Roberts, R, Lawrie, A, Angus, B, Khan, S, Janse, C, Ewer, K, Germain, R, Spencer, A, Hill, A

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 t... by Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 t... by Folegatti, PM, Bittaye, M, Flaxman, A, Lopez, FR, Bellamy, D, Kupke, A, Mair, C, Makinson, R, Sheridan, J, Rohde, C, Halwe, S, Jeong, Y, Park, Y-S, Kim, J-O, Song, M, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshal, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Becker, S, Lambe, T, Hill, A, Ewer, K, Gilbert, S

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study by Schmit, N, Topazian, HM, Natama, HM, Bellamy, D, Traoré, O, Somé, MA, Rouamba, T, Tahita, MC, Bonko, MDA, Sourabié, A, Sorgho, H, Stockdale, L, Provstgaard-Morys, S, Aboagye, J, Woods, D, Rapi, K, Datoo, MS, Ramos Lopez, F, Charles, GD, McCain, K, Ouedraogo, J-B, Hamaluba, M, Olotu, A, Dicko, A, Tinto, H, Hill, AVS, Ewer, KJ, Ghani, AC, Winskill, P

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial by Folegatti, PM, Ewer, KJ, Aley, PK, Angus, B, Becker, S, Belij-Rammerstorfer, S, Bellamy, D, Bibi, S, Bittaye, M, Clutterbuck, EA, Dold, C, Faust, SN, Finn, A, Flaxman, AL, Hallis, B, Heath, P, Jenkin, D, Lazarus, R, Makinson, R, Minassian, AM, Pollock, KM, Ramasamy, M, Robinson, H, Snape, M, Tarrant, R, Voysey, M, Green, C, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ, Oxford COVID Vaccine Trial Group

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses by Barrett, J, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD, Green, CM, Hill, AVS, Lambe, T, Pollard, AJ